The biotech firm reported a Q2 GAAP loss of $0.11 per share, aligning with expectations, and held $159.0 million in cash as of June 30, 2026.
Inhibikase Therapeutics reported a second-quarter GAAP loss of $0.11 per share, matching analyst estimates. The company’s net loss reflected ongoing research and development expenses for its pipeline of neurodegenerative disease treatments.
As of June 30, 2026, the company held $159.0 million in cash, cash equivalents, and marketable securities. This follows a recent equity offering of 25 million common shares, completed after the quarter’s close, aimed at bolstering liquidity.
The results provide insight into the firm’s financial runway as it advances clinical programs, though no immediate market reaction was disclosed.